Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Liraglutide reduces sST2 levels in diabetes patients
Last updated September 12, 2026
Key finding
Liraglutide treatment decreased plasma sST2 levels by 9% (beta = -14.9, p = 0.037).
Liraglutide treatment significantly reduced sST2 levels in obese patients with prediabetes or early T2DM, while lifestyle counseling had no significant effect.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Liraglutide treatment significantly reduced sST2 levels in obese patients with prediabetes or early T2DM, while lifestyle counseling had no significant effect.
Clinical relevance
These findings highlight the potential of liraglutide as a therapeutic option for reducing cardiovascular risk markers in obese patients with prediabetes or early T2DM. The lack of significant change with lifestyle counseling suggests that pharmacological interventions may be necessary for effective management of these patients' cardiovascular health.
Keep in mind
The study's sample size may limit the generalizability of findings. The effects of lifestyle counseling were not significant, raising questions about its efficacy. Long-term effects of liraglutide treatment were not assessed.
Published in
Journal Reference
Publication details and source links for this paper.
Paola S, Romina T, Annika M, et al. Liraglutide treatment reduces sST2 levels in obese patients with prediabetes or early T2DM. Cardiovascular Diabetology. 2022;21:36. doi:10.1186/s12933-022-01469-w
Main Effects
Liraglutide treatment decreased plasma sST2 levels by 9% (p = 0.037).
Liraglutide treatment decreased hs-Troponin I levels by 25% (p = 0.033).
Lifestyle counseling did not significantly change sST2 levels (4.42%, p = 0.49).
Lifestyle counseling resulted in a 19% increase in hs-Troponin I levels (p = 0.29).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Behavioral counseling, Liraglutide and Gal-3, hs-Troponin I, sST2.
This study contributes evidence to
Primary intervention
Behavioral counseling
Primary outcomes
- Gal-3
- hs-Troponin I
- sST2
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
231
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Diabetes Self-Management Education and Support
matched_intervention
Related evidence
Evidence topic
GLP-1 Receptor Agonists
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Liraglutide reduced sST2 levels by 9% (p = 0.037).
- Liraglutide decreased hs-Troponin I levels by 25% (p = 0.033).
- Lifestyle counseling did not significantly change sST2 or hs-Troponin I levels.
Who this applies to
- Obese patients with prediabetes.
- Individuals with early type 2 diabetes mellitus.
Keep in Mind
- Results may not apply to non-obese populations.
- The study did not evaluate long-term outcomes of liraglutide.
- Further research is needed to confirm findings in larger, diverse populations.
Between the Lines
- The study's sample size may limit the generalizability of findings.
- The effects of lifestyle counseling were not significant, raising questions about its efficacy.
- Long-term effects of liraglutide treatment were not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Diabetes Self-Management Education and Support (DSMES) Programs and Gal-3, Diabetes Self-Management Education and Support (DSMES) Programs and hs-Troponin I.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Diabetes Self-Management Education and Support (DSMES) Programs → Gal-3
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceBehavioral & Lifestyle
Diabetes Self-Management Education and Support (DSMES) Programs → hs-Troponin I
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Diabetes Self-Management Education and Support (DSMES) Programs Evidence Hub
All studies on Diabetes Self-Management Education and Support (DSMES) Programs
1 studies
intervention_hubContributes to Diabetes Self-Management Education and Support (DSMES) Programs evidence base.
Gal-3 Evidence Hub
All studies measuring Gal-3
1 studies
outcome_hubMeasures Gal-3 as a key outcome.
hs-Troponin I Evidence Hub
All studies measuring hs-Troponin I
1 studies
outcome_hubMeasures hs-Troponin I as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Behavioral counseling and Gal-3
Intervention: Behavioral counselingOutcome: Gal-3
1 results
All studies on Behavioral counseling and hs-Troponin I
Intervention: Behavioral counselingOutcome: hs-Troponin I
1 results
All studies on Behavioral counseling
Intervention: Behavioral counseling
1 results
All studies measuring Gal-3
Outcome: Gal-3
1 results
All studies measuring hs-Troponin I
Outcome: hs-Troponin I
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Liraglutide improve hs-troponin i?
Emerging Evidence
Liraglutide appears to improve hs-troponin i.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
hs-Troponin I
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Liraglutide improve sst2?
Emerging Evidence
Liraglutide appears to improve sst2.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
sST2
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Behavioral counseling improve gal-3?
Emerging Evidence
Current evidence does not show a clear benefit of Behavioral counseling for gal-3.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Gal-3
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Behavioral counseling improve hs-troponin i?
Emerging Evidence
Current evidence does not show a clear benefit of Behavioral counseling for hs-troponin i.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
hs-Troponin I
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsCBT improves diabetes management in patients with metabolic syndromeGLP-1RA improves metabolic outcomes in MASLDWeight loss improves metabolic outcomes in obese patients with diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.